Through its clinical studies, RECARDIO is actively engaged in the development of novel therapeutic approaches for cardiovascular diseases.
Phase 1 Study
The Phase 1 study of parenteral application of dutogliptin will evaluate the PK/PD and safety in healthy volunteers.
Phase 2b Study
The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.